Importance of ABCC1 for cancer therapy and prognosis

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Multidrug resistance (MDR) is a major challenge in cancer therapy, frequently driven by enhanced expression of ATP-binding cassette (ABC) transporters.
• ABC transporters are membrane proteins crucial for cellular defense, mediating xenobiotic efflux, which can paradoxically lead to tumor cell resistance to chemotherapeutics.
• The human ABC superfamily comprises 48 members, including several MDR-associated transporters, highlighting their significance in cancer treatment failure.

Purpose of the Study:

• To review current research on the association between gene and protein expression of ABC transporters, specifically ABCC1/MRP1, and their genetic variability with cancer prognosis and therapy outcomes.
• To identify knowledge gaps hindering the clinical application of ABC transporters as predictive markers for chemotherapy resistance.
• To highlight future research directions for leveraging ABC transporters in personalized cancer medicine.

Main Methods:

• Comprehensive literature review of studies investigating ABC transporter expression (gene and protein) and genetic variations in major cancers.
• Analysis of data linking these molecular factors to patient prognosis and response to chemotherapy.
• Synthesis of findings to identify key advances and remaining challenges.

Main Results:

• Enhanced expression of certain ABC transporters, including MRP1 (ABCC1), is strongly linked to multidrug resistance and poor therapeutic outcomes in various cancers.
• Tissue-specific expression patterns and genetic variability of ABCC1/MRP1 present significant potential as predictive biomarkers for chemotherapy resistance.
• Despite detailed structural and functional knowledge, clinical application is limited by gaps in understanding expression variability and clinical correlations.

Conclusions:

• ABC transporters, particularly ABCC1/MRP1, are critical determinants of multidrug resistance in cancer.
• Assessing ABCC1/MRP1 expression and genetic variability holds promise for individualizing cancer treatment strategies and predicting chemotherapy response.
• Further research is needed to bridge the gap between molecular understanding and clinical utility, paving the way for targeted therapies and improved patient outcomes.